Use: Labeled indications
- INDICATIONS AND USAGE Adapalene Cream, 0.1% is indicated for the topical treatment of acne vulgaris.
Full indications and usage US FDA label
INDICATIONS AND USAGE Adapalene Cream, 0.1% is indicated for the topical treatment of acne vulgaris.
Contraindications
CONTRAINDICATIONS Adapalene Cream, 0.1% should not be administered to individuals who are hypersensitive to adapalene or any of the components in the cream vehicle.
US FDA labelDosing: Adult
Dosage and administration (US label) US FDA label
DOSAGE AND ADMINISTRATION Adapalene Cream, 0.1% should be applied to affected areas of the skin, once daily at nighttime. A thin film of the cream should be applied to the skin areas where acne lesions appear, using enough to cover the entire affected areas lightly. A mild transitory sensation of warmth or slight stinging may occur shortly after the application of Adapalene Cream, 0.1%.
Dosing: Altered kidney function
No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Pediatric
Pediatric use (US label) US FDA label
Pediatric Use Safety and effectiveness in pediatric patients below the age of 12 have not been established.
Dosing: Older adult
Geriatric use (US label) US FDA label
Geriatric Use Clinical studies of Adapalene Cream, 0.1% were conducted in patients 12 to 30 years of age with acne vulgaris and therefore did not include subjects 65 years and older to determine whether they respond differently than younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.
Dosage forms
Philippines
- Topical gel: 1 mg/g, 3 mg/g
- ) cream: 1 mg/g
- ) gel: 1 mg/g
- Microsphere gel: 1 mg/g
Registered products in the Philippines
16 products registered with the Food and Drug Administration (FDA) Philippines list Adapalene as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products16
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AdaburAdapalene | 1 mg/g (0.1% w/w) Topical GelLaminated tube x 15 g (Box of 1's) | Rx | Rhydburg Pharmaceuticals Ltd.India | Genedrift Philippines OPC | DRP-14352 | Aug 24, 2028 | |
AdadocAdapalene | 1 mg/g (0.1% w/w) Topical Gelaminated tube x 15 g (Box of 1's) | Rx | Rhydburg Pharmaceuticals Ltd.India | Genedrift Philippines OPC | DRP-14351 | Aug 24, 2028 | |
AdanaAdapalene | 1 mg/g (0.1% w/w) Topical GelLami Tube x 10 g (Box of l's) | Rx | Rhydburg Pharmaceutical LimitedIndia | Aglobal Care Inc.Importer: Aglobal Care, Inc. | DR-XY47497 | Nov 29, 2026 | |
AdanaAdapalene | 1mg/g (0.1% w/w) Topical GelLami Tube x 10g (Box of 1's) | Rx | Rhydburg Pharmaceutical LimitedIndia | AGlobal Care, Inc. | DRP-12954 | Nov 29, 2026 | |
AdapasenzAdapalene | 1 mg/g (0.1%) Topical GelPE tube with white cap x 15 g (Box of 1's); PE tube with white cap x 30 g (Box of 1's) | Rx | Genuone Sciences Inc.Republic of Korea | Pharmaessence Inc.Importer: H & B Pharma International Inc. | DRP-8754-01 | Mar 11, 2030 | |
AdrylexAdapalene | 1 mg/g (0.1%) Topical GelPE tube with white cap Box of 1 x 15 g; PE tube with white cap Box of 1 x 30 g | Rx | Genuone Sciences Inc.Republic of Korea | Metro Pharma Philippines Inc.Importer: H & B Pharma International Inc. | DRP-8754 | Mar 11, 2030 | |
AknizolAdapalene | 1 mg/g (0.1 % w/w) Topical GelAluminum tube x 15 g (Box of 1's) | Rx | Agio Pharmaceuticals Ltd.India | Kaufmann Pharma Inc.Importer: Ambica International Corporation | DRP-8839 | Jul 2, 2030 | |
DifferinAdapalene | 0.1% (1 mg/g) CreamWhite collapsible aluminum tube with white polypropylene screw cap x 30 g (Box of 1's) 30g (Box of 1's) | Rx | Laboratoires GaldermaFrance | Importer: Galderma Philippines, Inc. | DR-XY27030 | Dec 6, 2030 | |
DifferinAdapalene | 0.1% (1 mg/g) Gel | Rx | Laboratoires Galderma | Galderma Philippines, Inc. | DR-XY22369 | Jan 29, 2027 | |
DifferinAdapalene | 3mg/g (0.3%) Topical GelWhite LDPE Tube with White Polypropylene Screw Cap x 15g and 30g (Box of 1's); White LDPE Tube with White Polypropylene Screw Cap x 2g (Box of 1's) as Physician sample 15g and 30g (Box of 1's) ; 2g (Box of 1's) as Physician sample | Rx | Galderma Brasil Ltda.Brazil | Galderma Philippines, Inc. | DR-XY43033 | Nov 28, 2028 | |
EladaAdapalene | 1 mg/g (0.1% w/w) Topical GelAluminum tube x 15 g (Box of 1’s) | Rx | Agio Pharmaceuticals Ltd.India | Elixir Pharma Inc.Importer: Ambica International Corporation | DRP-8839-01 | Jul 2, 2030 | |
Klenzit-MSAdapalene | 1 mg/g (0.1%) Microsphere Gel15 g Laminated Tube (Box of 1's); 5 g Laminated Tube as Physician's Sample (Box of 1's) | Rx | Glenmark Pharmaceuticals Ltd.India | Glenmark Philippines, Inc. | DRP-8041 | Mar 6, 2037 | |
RadapaAdapalene | 1 mg/g (0.1% w/w) Topical GelLaminated aluminum tube with white PET screw cap x 15 g | Rx | Front Pharmaceutical PLCChina | AMB HK Enterprises, Inc. | DRP-18996 | Oct 15, 2032 | |
(no brand name)Adapalene | 1 mg/g (0.1% w/w) Topical GelLami Tube x 15 g (Box of l's) | Rx | Rhydburg Pharmaceuticals Ltd.India | Khriz Pharma Trading Inc. | DRP-11563 | Mar 31, 2027 | |
(no brand name)Adapalene | 1 mg/g (0.1%) Topical GelOpaque White Plastic Tube x 15g and 30g with Polypropylene Cap (Box of 1's) | Rx | Amherst Laboratories, Inc.Philippines | UNILAB, Inc. | DRP-17547 | Jan 23, 2031 | |
(no brand name)Adapalene | 3 mg/g (0.3% w/w) Topical GelOpaque white plastic tube + opaque white PP cap x 15 g and 30 g (Box of 1's) | Rx | Amherst Laboratories, Inc.Philippines | Trader: UNILAB, INC. | DRP-14235 | Aug 1, 2028 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Warnings/Precautions
Warnings and precautions (US label) US FDA label
PRECAUTIONS General Certain cutaneous signs and symptoms of treatment such as erythema, dryness, scaling, burning, or pruritus may be experienced with use of Adapalene Cream, 0.1%. These are most likely to occur during the first two to four weeks of treatment, are mostly mild to moderate in intensity, and usually lessen with continued use of the medication.
Depending upon the severity of these side effects, patients should be instructed to reduce the frequency of application or discontinue use. If a reaction suggesting sensitivity or chemical irritation occurs, use of the medication should be discontinued. Exposure to sunlight, including sunlamps, should be minimized during use of adapalene.
Patients who normally experience high levels of sun exposure, and those with inherent sensitivity to sun, should be warned to exercise caution. Use of sunscreen products and protective clothing over treated areas is recommended when exposure cannot be avoided. Weather extremes, such as wind or cold, also may be irritating to patients under treatment with adapalene.
Avoid contact with the eyes, lips, angles of the nose, and mucous membranes. The product should not be applied to cuts, abrasions, eczematous or sunburned skin. As with other retinoids, use of “waxing” as a depilatory method should be avoided on skin treated with adapalene. Information for Patients Patients using Adapalene Cream, 0.1% should receive the following information and instructions: 1.
This medication is to be used only as directed by the physician. 2. It is for external use only. 3. Avoid contact with the eyes, lips, angles of the nose, and mucous membranes. 4. Cleanse area with a mild or soapless cleanser before applying this medication. 5. Moisturizers may be used if necessary; however, products containing alpha hydroxy or glycolic acids should be avoided. 6.
Exposure of the eye to this medication may result in reactions such as swelling, conjunctivitis, and eye irritation. 7. This medication should not be applied to cuts, abrasions, eczematous or sunburned skin. 8. Wax epilation should not be performed on treated skin due to the potential for skin erosions. 9. During the early weeks of therapy, an apparent exacerbation of acne may occur.
This is due to the action of this medication on previously unseen lesions and should not be considered a reason to discontinue therapy. Overall clinical benefit may be noticed after two weeks of therapy, but at least eight weeks are required to obtain consistent beneficial effects. Drug Interactions As Adapalene Cream, 0.1% has the potential to produce local irritation in some patients, concomitant use of other potentially irritating topical products (medicated or abrasive soaps and cleansers, soaps and cosmetics that have a strong drying effect, and products with high concentrations of alcohol, astringents, spices or lime rind) should be approached with caution.
Particular caution should be exercised in using preparations containing sulfur, resorcinol, or salicylic acid in combination with Adapalene Cream, 0.1%. If these preparations have been used, it is advisable not to start therapy with Adapalene Cream, 0.1% until the effects of such preparations in the skin have subsided. Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenicity studies with adapalene have been conducted in mice at topical doses of 0.4, 1.3, and 4.0 mg/kg/day, and in rats at oral doses of 0.15, 0.5, and 1.5 mg/kg/day.
These doses are up to 8 times (mice) and 6 times (rats) in terms of mg/m 2 /day the maximum potential exposure at the recommended topical human dose (MRHD), assumed to be 2.5 grams Adapalene Cream, 0.1%, which is approximately 1.5 mg/m 2 adapalene. In the oral study, increased incidence of benign and malignant pheochromocytomas in the adrenal medullas of male rats was observed.
No photocarcinogenicity studies were conducted. Animal studies have shown an increased risk of skin neoplasms with the use of pharmacologically similar drugs (e.g., retinoids) when exposed to UV irradiation in the laboratory or to sunlight. Although the significance of these studies to human use is not clear, patients should be advised to avoid or minimize exposure to either sunlight or artificial UV irradiation sources.
Adapalene did not exhibit mutagenic or genotoxic effects in vivo (mouse micronucleus test) and in vitro (Ames test, Chinese hamster ovary cell assay, mouse lymphoma TK assay) studies. Reproductive function and fertility studies were conducted in rats administered oral doses of adapalene in amounts up to 20 mg/kg/day (up to 80 times the MRHD based on mg/m 2 comparisons).
No effects of adapalene were found on the reproductive performance or fertility of the F 0 males or females. There were also no detectable effects on the growth, development and subsequent reproductive function of the F 1 generation. Pregnancy Teratogenic effects Pregnancy category C No teratogenic effects were seen in rats at oral doses of 0.15 to 5.0 mg/kg/day adapalene (up to 20 times the MRHD based on mg/m 2 comparisons).
However, adapalene administered orally at doses of ≥ 25 mg/kg, (100 times the MRHD for rats or 200 times MRHD for rabbits) has been shown to be teratogenic. Cutaneous teratology studies in rats and rabbits as doses of 0.6, 2.0, and 6.0 mg/kg/day (24 times MRHD for rats or 48 times the MRHD for rabbits) exhibited on fetotoxicity and only minimal increases in supernumerary ribs in rats.
There are no adequate and well-controlled studies in pregnant women. Adapalene should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Nursing Mothers It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Adapalene Cream, 0.1% is administered to a nursing woman.
Pediatric Use Safety and effectiveness in pediatric patients below the age of 12 have not been established. Geriatric Use Clinical studies of Adapalene Cream, 0.1% were conducted in patients 12 to 30 years of age with acne vulgaris and therefore did not include subjects 65 years and older to determine whether they respond differently than younger subjects.
Other reported clinical experience has not identified differences in responses between the elderly and younger patients.
Drug interactions
Drug interactions (US label) US FDA label
Drug Interactions As Adapalene Cream, 0.1% has the potential to produce local irritation in some patients, concomitant use of other potentially irritating topical products (medicated or abrasive soaps and cleansers, soaps and cosmetics that have a strong drying effect, and products with high concentrations of alcohol, astringents, spices or lime rind) should be approached with caution. Particular caution should be exercised in using preparations containing sulfur, resorcinol, or salicylic acid in combination with Adapalene Cream, 0.1%.
If these preparations have been used, it is advisable not to start therapy with Adapalene Cream, 0.1% until the effects of such preparations in the skin have subsided.
Adverse reactions
Adverse reactions (US label) US FDA label
ADVERSE REACTIONS In controlled clinical trials, local cutaneous irritation was monitored in 285 acne patients who used Adapalene Cream, 0.1% once daily for 12 weeks. The frequency and severity of erythema, scaling, dryness, pruritus and burning were assessed during these studies. The incidence of local cutaneous irritation with Adapalene Cream, 0.1% from the controlled clinical studies is provided in the following table: Incidence of Local Cutaneous Irritation with Adapalene Cream, 0.1% from Controlled Clinical Studies (N=285) None Mild Moderate Severe Erythema 52% (148) 38% (108) 10% (28) ‹1% (1) Scaling 58% (166) 35% (100) 6% (18) ‹1% (1) Dryness 48% (136) 42% (121) 9% (26) ‹1% (2) Pruritus (persistent) 74% (211) 21% (61) 4% (12) ‹1% (1) Burning/Stinging (persistent) 71% (202) 24% (69) 4% (12) ‹1% (2) Other reported local cutaneous adverse events in patients who used Adapalene Cream, 0.1% once daily included: sunburn (2%), skin discomfort-burning and stinging (1%) and skin irritation (1%).
Events occurring in less than 1% of patients treated with Adapalene Cream, 0.1% included: acne flare, dermatitis and contact dermatitis, eyelid edema, conjunctivitis, erythema, pruritus, skin discoloration, rash, and eczema.
Adverse reaction frequency tables (US label) US FDA label
| None | Mild | Moderate | Severe | |
| Erythema | 52% (148) | 38% (108) | 10% (28) | ‹1% (1) |
| Scaling | 58% (166) | 35% (100) | 6% (18) | ‹1% (1) |
| Dryness | 48% (136) | 42% (121) | 9% (26) | ‹1% (2) |
| Pruritus (persistent) | 74% (211) | 21% (61) | 4% (12) | ‹1% (1) |
| Burning/Stinging (persistent) | 71% (202) | 24% (69) | 4% (12) | ‹1% (2) |
Pregnancy considerations
Pregnancy (US label) US FDA label
Pregnancy Teratogenic effects Pregnancy category C No teratogenic effects were seen in rats at oral doses of 0.15 to 5.0 mg/kg/day adapalene (up to 20 times the MRHD based on mg/m 2 comparisons). However, adapalene administered orally at doses of ≥ 25 mg/kg, (100 times the MRHD for rats or 200 times MRHD for rabbits) has been shown to be teratogenic.
Cutaneous teratology studies in rats and rabbits as doses of 0.6, 2.0, and 6.0 mg/kg/day (24 times MRHD for rats or 48 times the MRHD for rabbits) exhibited on fetotoxicity and only minimal increases in supernumerary ribs in rats. There are no adequate and well-controlled studies in pregnant women. Adapalene should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Breastfeeding considerations
Lactation (US label) US FDA label
Nursing Mothers It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Adapalene Cream, 0.1% is administered to a nursing woman.
Mechanism of action
Mechanism of Action Adapalene acts on retinoid receptors. Biochemical and pharmacological profile studies have demonstrated that adapalene is a modulator of cellular differentiation, keratinization, and inflammatory processes all of which represent important features in the pathology of acne vulgaris. Mechanistically, adapalene binds to specific retinoic acid nuclear receptors but does not bind to the cytosolic receptor protein.
Although the exact mode of action of adapalene is unknown, it is suggested that topical adapalene normalizes the differentiation of follicular epithelial cells resulting in decreased microcomedone formation.
US FDA labelPharmacokinetics
Excretion appears to be primarily by the biliary route.
Pharmacokinetics (US label) US FDA label
Pharmacokinetics Absorption of adapalene from Adapalene Cream, 0.1% through human skin is low. In a pharmacokinetic study with six acne patients treated once daily for 5 days with 2 grams of Adapalene Cream, 0.1% applied to 1000 cm 2 of acne involved skin, there were no quantifiable amounts (limit of quantification = 0.35 ng/mL) of adapalene in the plasma samples from any patient. Excretion appears to be primarily by the biliary route.
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Adapalene · Padagis Israel Pharmaceuticals Ltd [US FDA-approved label, version 4, July 25, 2023]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94cf9af1-afab-4064-a2ca-619b54218262
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .